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We would like to thank Dr Wiedermann for his interest in our
paper [1].
It is well established that IL-6 has been associated with
anti-inflammatory properties, as pointed out by Dr
Wiedermann. Although not a proinflammatory cytokine, IL-6 is
produced by several cells as a result of previous stimulation
by tumour necrosis factor (TNF)-α and IL-1. Therefore, the
concentration of IL-6 has been considered to be a marker of
the inflammatory reaction, as well as the preceding TNF-α
and IL-1 responses, and in several studies it was shown to
correlate with prognosis in patients with severe sepsis and
septic shock [2–4]. Furthermore, persistently elevated levels
of IL-6 have been associated with the development of
multiple organ dysfunction syndrome [5].
The primary end-point of our study was to investigate whether
the biological effects of endotoxin, as measured using TNF-α
and IL-6 responses, could be neutralized by antibiotics. The
early peak cytokine response after 1 hour (for TNF-α) and
2 hours (for IL-6) was chosen because both antibiotics in vitro
had been shown to induce protection against oxidative injury,
which induces an inflammatory response that might influence
the results. A secondary end-point was whether the antibiotic
treatment could affect cytokine concentrations in an animal
model. The lower concentration of IL-6 during the last period
of the experiment might be consistent with a reduction in
oxidative stress and a concomitant proinflammatory response.
In comparison with IL-6, the TNF-α response is often of lesser
magnitude and of more transient character, which increases
the statistical β error and makes it more difficult to
demonstrate a reduction even if there is one.
It was emphasized that our data did not rule out other
mechanisms. However, even if IL-6 does not have
proinflammatory properties per se, then the most likely
explanation was that IL-6 indicated the presence of an
inflammatory response and that the reduction in IL-6
represented an anti-inflammatory effect caused by
tobramycin and ceftazidime.
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